Trial Profile
Phase II Study of Carboplatin +Docetaxel +Bevacizumab in Chemo-Naive Patients with stage IIIB and IV Non-Squamous Non-Small-Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Oct 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan record.
- 15 May 2012 New trial record